Aoxing Pharmaceutical Company, Inc.
AOXG · OTC
6/30/2025 | 6/30/2024 | 6/30/2016 | 6/30/2015 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $32 | $25 |
| % Growth | – | -100% | 26.9% | – |
| Cost of Goods Sold | $0 | $0 | $8 | $6 |
| Gross Profit | $0 | $0 | $25 | $20 |
| % Margin | – | – | 75.9% | 77.7% |
| R&D Expenses | $0 | $0 | $3 | $0 |
| G&A Expenses | $0 | $0 | $3 | $3 |
| SG&A Expenses | $0 | $0 | $15 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $12 | $7 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $18 | $11 |
| Operating Income | -$0 | -$0 | $6 | $9 |
| % Margin | – | – | 19.3% | 34.1% |
| Other Income/Exp. Net | $0 | -$0 | -$3 | -$6 |
| Pre-Tax Income | $0 | -$0 | $3 | $3 |
| Tax Expense | $0 | $0 | $1 | -$3 |
| Net Income | $0 | -$0 | $2 | $5 |
| % Margin | – | – | 6.4% | 21.6% |
| EPS | 0 | -0 | 0.03 | 0.09 |
| % Growth | 330.2% | -100.1% | -66.7% | – |
| EPS Diluted | 0 | -0 | 0.03 | 0.09 |
| Weighted Avg Shares Out | 381 | 341 | 74 | 63 |
| Weighted Avg Shares Out Dil | 381 | 341 | 75 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $3 | $6 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $0 | -$0 | $7 | $9 |
| % Margin | – | – | 22.4% | 36.7% |